SLC16A1 and breast cancer: After the 80 BC patients were divided into SLC16A1-AS1 low-expression (n = 40) and SLC16A1-AS1 high-expression (n = 40) groups with the cutoff value of SLC16A1-AS1 median expression in BC tissues, the survival curves of the BC patients with SLC16A1-AS1 high-expression and SLC16A1-AS1 low-expression levels were plotted by Kaplan–Meier analysis, which showed a poor prognosis in BC patients with lower SLC16A1-AS1 expression (Figure 1D).